|  |
December 2004 Stock Report
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| HUMAN GENOME SCIENCES |
$12.02 |
81% |
-9% |
$1,567 |
$930 |
$504 |
$1,141 |
$1.0 |
-$234 |
4.0 |
Dec-93 |
4.0 |
$3.00 |
$176 |
| INCYTE CORP. |
$9.99 |
90% |
46% |
$738 |
$534 |
$418 |
$622 |
$1.4 |
-$254 |
2.1 |
Nov-93 |
5.3 |
$1.88 |
$47 |
| MILLENNIUM PHARMACEUTICALS |
$12.14 |
61% |
-35% |
$3,714 |
$813 |
$204 |
$3,105 |
$2.0 |
-$216 |
3.8 |
May-96 |
4.0 |
$3.00 |
$273 |
| MYRIAD GENETICS |
$22.51 |
89% |
75% |
$690 |
$119 |
$0 |
$571 |
$1.1 |
-$42 |
2.8 |
Oct-95 |
2.5 |
$9.00 |
$163 |
| OSCIENT PHARMACEUTICALS |
$3.65 |
51% |
17% |
$274 |
$66 |
$24 |
$232 |
$3.7 |
-$69 |
1.0 |
Feb-82 |
0.3 |
$11.00 |
$90 |
| 1st Generation Genomics Average |
|
74% |
19% |
$1,397 |
$492 |
|
$1,134 |
$1.8 |
-$163 |
2.7 |
|
3.2 |
|
|
| 1st Generation Genomics Median |
|
81% |
17% |
$738 |
$534 |
|
$622 |
$1.4 |
-$216 |
2.8 |
|
4.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AFFYMETRIX |
$36.55 |
96% |
49% |
$2,228 |
$216 |
$120 |
$2,132 |
$2.4 |
na |
na |
Jun-96 |
4.9 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$7.53 |
76% |
13% |
$223 |
$51 |
$2 |
$174 |
$0.4 |
-$38 |
1.3 |
Dec-99 |
0.5 |
$16.00 |
$333 |
| CEPHEID |
$9.94 |
76% |
4% |
$418 |
$71 |
$10 |
$357 |
$2.0 |
-$15 |
4.8 |
Jun-00 |
1.7 |
$6.00 |
$158 |
| CIPHERGEN BIOSYSTEMS |
$4.30 |
37% |
-62% |
$126 |
$29 |
$32 |
$128 |
$0.4 |
-$53 |
0.6 |
Sep-00 |
0.3 |
$16.00 |
$417 |
| COMBIMATRIX CORP. |
$3.97 |
43% |
19% |
$123 |
$19 |
$0 |
$104 |
$1.8 |
na |
na |
na |
na |
na |
na |
| COMPUGEN LTD |
$5.15 |
64% |
2% |
$142 |
$20 |
$0 |
$122 |
$0.7 |
na |
na |
Sep-00 |
0.5 |
$10.00 |
$0 |
| ILLUMINA |
$9.48 |
93% |
34% |
$361 |
$25 |
$25 |
$361 |
$10.0 |
-$14 |
1.8 |
Jul-00 |
0.6 |
$16.00 |
$515 |
| NANOGEN |
$7.36 |
49% |
-18% |
$249 |
$51 |
$1 |
$200 |
$1.5 |
-$52 |
1.0 |
Apr-98 |
0.7 |
$11.00 |
$197 |
| ORCHID BIOSCIENCES |
$11.50 |
81% |
24% |
$257 |
$32 |
$2 |
$227 |
$0.6 |
-$8 |
3.8 |
May-00 |
1.4 |
$8.00 |
$263 |
| SEQUENOM |
$1.44 |
32% |
-55% |
$57 |
$45 |
$15 |
$27 |
$0.1 |
-$40 |
1.1 |
Feb-00 |
0.1 |
$26.00 |
$609 |
| TRANSGENOMIC |
$1.15 |
35% |
-43% |
$33 |
$1 |
$6 |
$38 |
$0.2 |
-$16 |
0.0 |
Jul-00 |
0.1 |
$15.00 |
$317 |
| Genomic Supply Average |
|
62% |
-3% |
$383 |
$51 |
|
$352 |
$1.8 |
-$29 |
1.8 |
|
1.1 |
|
|
| Genomic Supply Median |
|
64% |
4% |
$223 |
$32 |
|
$174 |
$0.7 |
-$27 |
1.2 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ARENA PHARMACEUTICALS |
$6.70 |
94% |
8% |
$178 |
$132 |
$0 |
$45 |
$0.2 |
-$68 |
1.9 |
Jul-00 |
0.4 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$13.75 |
76% |
-1% |
$1,008 |
$727 |
$6 |
$286 |
$0.4 |
-$88 |
8.3 |
Feb-00 |
0.1 |
$225.00 |
na |
| CURAGEN CORP. |
$7.16 |
75% |
-2% |
$359 |
$382 |
$240 |
$217 |
$0.7 |
-$113 |
3.4 |
Mar-98 |
1.2 |
$5.75 |
$143 |
| DECODE GENETICS |
$7.81 |
57% |
-5% |
$426 |
$84 |
$62 |
$404 |
$1.0 |
-$53 |
1.6 |
Jul-00 |
0.4 |
$18.00 |
$818 |
| EXELIXIS |
$9.50 |
89% |
35% |
$711 |
$176 |
$108 |
$642 |
$1.1 |
-$117 |
1.5 |
Apr-00 |
0.7 |
$13.00 |
$520 |
| GENAISSANCE PHARMACEUTICALS |
$2.13 |
48% |
-29% |
$66 |
$5 |
$11 |
$73 |
$0.7 |
-$31 |
0.1 |
Aug-00 |
0.2 |
$13.00 |
$288 |
| GENE LOGIC |
$3.68 |
58% |
-29% |
$116 |
$110 |
$1 |
$8 |
$0.0 |
-$18 |
6.3 |
Nov-97 |
0.5 |
$8.00 |
$109 |
| GENENCOR INTERNATIONAL |
$16.40 |
97% |
4% |
$978 |
$177 |
$65 |
$866 |
$0.7 |
na |
na |
Jul-00 |
0.9 |
$18.00 |
$1,045 |
| ICORIA INC. |
$0.65 |
38% |
-56% |
$24 |
$12 |
$7 |
$19 |
$0.1 |
-$15 |
0.8 |
May-00 |
0.1 |
$7.00 |
$177 |
| LARGE SCALE BIOLOGY CORP. |
$1.26 |
46% |
-32% |
$39 |
$8 |
$0 |
$32 |
$0.4 |
-$16 |
0.5 |
Aug-00 |
0.1 |
$17.00 |
$388 |
| LEXICON GENETICS |
$7.76 |
94% |
32% |
$492 |
$132 |
$56 |
$416 |
$0.7 |
-$67 |
2.0 |
Apr-00 |
0.4 |
$22.00 |
$1,037 |
| LYNX THERAPEUTICS |
$3.82 |
56% |
-40% |
$29 |
$3 |
$0 |
$26 |
$0.3 |
-$14 |
0.2 |
na |
na |
na |
na |
| MAXYGEN |
$12.79 |
100% |
20% |
$452 |
$115 |
$0 |
$338 |
$1.2 |
-$54 |
2.1 |
Dec-99 |
0.8 |
$16.00 |
$465 |
| NUVELO |
$9.85 |
60% |
-6% |
$317 |
$92 |
$19 |
$244 |
$3.9 |
-$44 |
2.1 |
Sep-97 |
0.7 |
$14.00 |
$175 |
| RIGEL PHARMACEUTICALS |
$24.42 |
84% |
27% |
$478 |
$84 |
$3 |
$397 |
$3.1 |
-$49 |
1.7 |
Nov-00 |
3.5 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$6.00 |
81% |
10% |
$151 |
$39 |
$0 |
$113 |
$2.0 |
-$13 |
2.9 |
Apr-00 |
0.4 |
$15.00 |
$312 |
| ZYMOGENETICS |
$23.00 |
93% |
48% |
$1,316 |
$265 |
$51 |
$1,102 |
$3.1 |
-$98 |
2.7 |
Feb-01 |
1.9 |
$12.00 |
$547 |
| Genomic Targets Average |
|
73% |
-1% |
$420 |
$150 |
|
$307 |
$1.1 |
-$54 |
2.4 |
|
0.8 |
|
|
| Genomic Targets Median |
|
76% |
-1% |
$359 |
$110 |
|
$244 |
$0.7 |
-$51 |
2.0 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXION PHARMACEUTICALS |
$25.20 |
96% |
48% |
$701 |
$207 |
$120 |
$614 |
$3.2 |
-$80 |
2.6 |
Feb-96 |
3.1 |
$8.25 |
$62 |
| ATHEROGENICS |
$23.56 |
56% |
59% |
$880 |
$101 |
$100 |
$879 |
$9.1 |
-$66 |
1.5 |
Aug-00 |
2.9 |
$8.00 |
$184 |
| CONNETICS CORP. |
$24.29 |
80% |
34% |
$865 |
$50 |
$90 |
$905 |
$4.2 |
na |
na |
Feb-96 |
2.2 |
$11.00 |
$81 |
| CORTECH |
$3.14 |
89% |
9% |
$11 |
$11 |
$0 |
($0) |
($0.2) |
-$1 |
22.8 |
Nov-92 |
0.1 |
$40.00 |
$116 |
| CYPRESS BIOSCIENCE |
$14.06 |
84% |
-6% |
$421 |
$119 |
$0 |
$302 |
$20.1 |
-$29 |
4.1 |
Dec-83 |
0.2 |
$80.00 |
$33 |
| ICOS CORP. |
$28.28 |
63% |
-31% |
$1,797 |
$326 |
$279 |
$1,750 |
$2.6 |
-$208 |
1.6 |
Jun-91 |
3.5 |
$8.00 |
$172 |
| INKINE PHARMACEUTICAL CO. |
$5.43 |
82% |
12% |
$265 |
$11 |
$1 |
$255 |
$4.5 |
na |
na |
na |
na |
na |
na |
| LA JOLLA PHARMACEUTICAL CO. |
$1.67 |
40% |
-61% |
$103 |
$47 |
$2 |
$58 |
$0.5 |
-$34 |
1.4 |
Jun-94 |
0.3 |
$5.00 |
$43 |
| PROTEIN DESIGN LABS |
$20.66 |
75% |
15% |
$1,973 |
$452 |
$259 |
$1,780 |
$3.2 |
-$50 |
9.0 |
Jan-92 |
2.8 |
$7.50 |
$191 |
| TANOX |
$15.20 |
76% |
2% |
$668 |
$130 |
$5 |
$543 |
$4.6 |
-$16 |
7.9 |
Apr-00 |
0.5 |
$28.50 |
$1,193 |
| Autoimmune Average |
|
74% |
8% |
$768 |
$145 |
|
$709 |
$5.2 |
-$60 |
6.4 |
|
1.7 |
|
|
| Autoimmune Median |
|
78% |
11% |
$685 |
$110 |
|
$578 |
$3.7 |
-$42 |
3.3 |
|
2.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALLOS THERAPEUTICS |
$2.40 |
41% |
-33% |
$75 |
$35 |
$0 |
$40 |
$0.7 |
-$29 |
1.2 |
Mar-00 |
0.1 |
$18.00 |
$604 |
| ANTIGENICS |
$10.12 |
81% |
-11% |
$461 |
$121 |
$8 |
$348 |
$1.6 |
-$69 |
1.8 |
Feb-00 |
0.6 |
$18.00 |
$429 |
| APHTON CORP. |
$3.11 |
36% |
-48% |
$118 |
$56 |
$11 |
$72 |
$1.4 |
-$27 |
2.1 |
na |
na |
na |
na |
| ARIAD PHARMACEUTICALS |
$7.43 |
54% |
0% |
$391 |
$82 |
$8 |
$317 |
$6.1 |
-$37 |
2.2 |
May-94 |
0.9 |
$8.00 |
$124 |
| AVI BIOPHARMA |
$2.35 |
49% |
-42% |
$85 |
$30 |
$0 |
$55 |
$0.5 |
-$29 |
1.0 |
Jun-97 |
0.3 |
$9.00 |
$103 |
| BIOMIRA |
$2.41 |
58% |
63% |
$175 |
$23 |
$0 |
$152 |
$1.0 |
-$15 |
1.6 |
Jun-87 |
0.5 |
$4.40 |
$43 |
| BOSTON LIFE SCIENCES |
$0.57 |
33% |
-54% |
$20 |
$6 |
$4 |
$18 |
$1.5 |
-$17 |
0.3 |
na |
na |
na |
na |
| CANCERVAX |
$10.85 |
81% |
14% |
$290 |
$81 |
$4 |
$214 |
$1.4 |
-$51 |
1.6 |
Oct-03 |
0.9 |
$12.00 |
$308 |
| CELGENE CORP. |
$26.52 |
81% |
-41% |
$4,366 |
$714 |
$400 |
$4,052 |
$6.0 |
na |
na |
Jul-87 |
7.2 |
$3.66 |
$55 |
| CELL THERAPEUTICS |
$8.14 |
81% |
-6% |
$497 |
$144 |
$192 |
$544 |
$1.5 |
-$150 |
1.0 |
Mar-97 |
0.8 |
$10.00 |
$166 |
| CORIXA CORP. |
$3.64 |
50% |
-40% |
$216 |
$122 |
$153 |
$247 |
$0.7 |
-$42 |
2.9 |
Oct-97 |
0.3 |
$13.00 |
$152 |
| CYTOGEN CORP. |
$11.52 |
69% |
6% |
$178 |
$22 |
$0 |
$156 |
$2.6 |
-$18 |
1.2 |
Jun-86 |
0.9 |
$13.00 |
$148 |
| CYTOKINETICS |
$10.25 |
57% |
na |
$291 |
$19 |
$2 |
$274 |
$1.7 |
-$37 |
0.5 |
Apr-04 |
0.8 |
$13.00 |
$368 |
| DENDREON CORP. |
$10.78 |
64% |
34% |
$636 |
$189 |
$3 |
$449 |
$3.1 |
-$63 |
3.0 |
Jun-00 |
1.1 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$14.30 |
95% |
183% |
$241 |
$52 |
$2 |
$191 |
$3.8 |
-$17 |
3.1 |
Jan-92 |
2.4 |
$6.00 |
$30 |
| ENTREMED |
$3.24 |
66% |
-2% |
$120 |
$27 |
$0 |
$94 |
$2.1 |
-$18 |
1.5 |
Jun-96 |
0.2 |
$15.00 |
$182 |
| EXEGENICS |
$0.34 |
26% |
-62% |
$6 |
$9 |
$0 |
($4) |
($0.5) |
-$2 |
4.5 |
na |
na |
na |
na |
| GENAERA CORP. |
$3.42 |
65% |
5% |
$194 |
$26 |
$0 |
$169 |
$7.3 |
-$16 |
1.6 |
Dec-91 |
0.4 |
$9.00 |
$62 |
| GENITOPE |
$17.04 |
97% |
86% |
$408 |
$77 |
$0 |
$331 |
$3.6 |
-$27 |
2.9 |
Oct-03 |
1.9 |
$9.00 |
$145 |
| GENTA INC. |
$1.76 |
11% |
-83% |
$141 |
$39 |
$45 |
$147 |
$1.0 |
-$117 |
0.3 |
Dec-91 |
0.0 |
$100.00 |
$123 |
| GERON CORP. |
$7.97 |
64% |
-20% |
$364 |
$95 |
$5 |
$274 |
$5.2 |
-$36 |
2.7 |
Jul-96 |
1.0 |
$8.00 |
$77 |
| GTX |
$13.49 |
84% |
na |
$333 |
$77 |
$0 |
$255 |
$6.1 |
-$18 |
4.3 |
Feb-04 |
0.9 |
$14.50 |
$358 |
| IMCLONE SYSTEMS |
$46.08 |
53% |
16% |
$3,813 |
$309 |
$240 |
$3,744 |
$8.9 |
na |
na |
Nov-91 |
6.6 |
$7.00 |
$107 |
| IMMUNOGEN |
$8.84 |
71% |
75% |
$361 |
$103 |
$0 |
$258 |
$2.2 |
na |
na |
Nov-89 |
0.9 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$3.04 |
49% |
-33% |
$164 |
$15 |
$17 |
$166 |
$1.5 |
-$27 |
0.6 |
Oct-83 |
2.4 |
$1.25 |
$25 |
| MAXIM PHARMACEUTICALS |
$3.02 |
29% |
-66% |
$86 |
$61 |
$1 |
$27 |
$0.3 |
-$47 |
1.3 |
Jul-96 |
0.4 |
$7.50 |
$50 |
| MEDAREX |
$10.78 |
93% |
73% |
$921 |
$298 |
$289 |
$912 |
$2.2 |
-$174 |
1.7 |
Jun-91 |
3.6 |
$3.00 |
$31 |
| NEOPHARM |
$12.51 |
55% |
-31% |
$291 |
$88 |
$0 |
$203 |
$1.9 |
-$59 |
1.5 |
Jan-96 |
3.9 |
$3.18 |
$28 |
| NEORX CORP. |
$2.09 |
35% |
-50% |
$64 |
$28 |
$4 |
$41 |
$1.1 |
-$19 |
1.5 |
Aug-88 |
0.1 |
$28.00 |
$102 |
| OSI PHARMACEUTICALS |
$74.85 |
76% |
132% |
$3,790 |
$671 |
$310 |
$3,429 |
$7.1 |
-$199 |
3.4 |
Apr-86 |
12.5 |
$6.00 |
$53 |
| OXIGENE |
$5.50 |
49% |
-32% |
$92 |
$37 |
$0 |
$55 |
$5.0 |
-$11 |
3.3 |
Oct-93 |
0.9 |
$6.00 |
$28 |
| PHARMION |
$42.21 |
72% |
177% |
$1,336 |
$291 |
$0 |
$1,045 |
$17.7 |
-$40 |
7.3 |
Nov-03 |
3.0 |
$14.00 |
$358 |
| PRAECIS PHARMACEUTICALS |
$1.90 |
25% |
-70% |
$100 |
$112 |
$32 |
$20 |
$0.1 |
-$59 |
1.9 |
Apr-00 |
0.2 |
$10.00 |
$400 |
| PROGENICS PHARMACEUTICALS |
$17.16 |
73% |
-9% |
$296 |
$36 |
$0 |
$260 |
$2.3 |
-$44 |
0.8 |
Nov-97 |
2.1 |
$8.00 |
$70 |
| QLT |
$16.08 |
52% |
-15% |
$1,119 |
$537 |
$173 |
$755 |
$2.3 |
na |
na |
Sep-86 |
14.9 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$3.70 |
45% |
-45% |
$165 |
$57 |
$6 |
$114 |
$1.1 |
-$12 |
4.9 |
Mar-92 |
0.5 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$6.53 |
60% |
-24% |
$274 |
$16 |
$0 |
$258 |
$2.4 |
-$144 |
0.1 |
Mar-01 |
0.9 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$6.66 |
66% |
-20% |
$97 |
$22 |
$0 |
$74 |
$4.6 |
-$9 |
2.5 |
na |
na |
na |
na |
| SUPERGEN |
$7.05 |
50% |
-36% |
$354 |
$26 |
$6 |
$334 |
$2.9 |
-$85 |
0.3 |
Mar-96 |
1.2 |
$6.00 |
$21 |
| TAPESTRY PHARMACEUTICALS |
$0.97 |
29% |
-51% |
$32 |
$27 |
$6 |
$11 |
$0.2 |
-$26 |
1.1 |
Apr-94 |
0.2 |
$5.00 |
$41 |
| VERNALIS |
$3.20 |
67% |
34% |
$12 |
$7 |
$0 |
$5 |
$0.1 |
-$52 |
0.1 |
May-96 |
0.4 |
$7.20 |
$178 |
| XCYTE THERAPIES |
$2.76 |
56% |
na |
$46 |
$35 |
$2 |
$13 |
$0.2 |
-$24 |
1.4 |
Mar-04 |
0.3 |
$8.00 |
$134 |
| XENOVA PLC |
$1.30 |
46% |
-29% |
$341 |
$26 |
$0 |
$315 |
$2.2 |
na |
na |
Jul-94 |
0.1 |
$16.00 |
$90 |
| Cancer Average |
|
58% |
-1% |
$543 |
$113 |
|
$475 |
$2.9 |
-$49 |
2.0 |
|
2.0 |
|
|
| Cancer Median |
|
57% |
-20% |
$241 |
$52 |
|
$203 |
$2.1 |
-$32 |
1.6 |
|
0.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CORGENTECH |
$8.28 |
38% |
na |
$230 |
$146 |
$1 |
$86 |
$1.2 |
-$35 |
4.1 |
Feb-04 |
0.5 |
$16.00 |
$445 |
| CV THERAPEUTICS |
$23.00 |
93% |
56% |
$746 |
$409 |
$297 |
$634 |
$2.4 |
-$149 |
2.7 |
Nov-96 |
2.9 |
$8.00 |
$48 |
| ENCYSIVE PHARMACEUTICALS |
$9.93 |
83% |
11% |
$573 |
$94 |
$2 |
$481 |
$5.2 |
-$49 |
1.9 |
Dec-93 |
1.5 |
$6.75 |
$88 |
| MEDICINES COMPANY |
$28.80 |
80% |
-2% |
$1,386 |
$129 |
$0 |
$1,256 |
$6.6 |
na |
na |
Sep-00 |
1.8 |
$16.00 |
$506 |
| MYOGEN |
$8.07 |
42% |
-44% |
$288 |
$82 |
$3 |
$210 |
$3.7 |
-$53 |
1.6 |
Oct-03 |
0.6 |
$14.00 |
$358 |
| NITROMED |
$26.65 |
98% |
271% |
$702 |
$173 |
$0 |
$529 |
$12.9 |
-$18 |
9.4 |
Nov-03 |
2.4 |
$11.00 |
$264 |
| QUESTCOR PHARMACEUTICALS |
$0.53 |
46% |
-28% |
$27 |
$7 |
$4 |
$24 |
$0.5 |
-$2 |
4.1 |
na |
na |
na |
na |
| Cardiovascular Average |
|
68% |
44% |
$565 |
$149 |
|
$460 |
$4.6 |
-$51 |
4.0 |
|
1.6 |
|
|
| Cardiovascular Median |
|
80% |
4% |
$573 |
$129 |
|
$481 |
$3.7 |
-$42 |
3.4 |
|
1.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACCELRYS |
$7.80 |
34% |
-24% |
$207 |
$141 |
$0 |
$66 |
$0.1 |
-$25 |
5.7 |
Dec-95 |
0.5 |
$16.00 |
$158 |
| ALBANY MOLECULAR RESEARCH |
$11.14 |
64% |
-26% |
$354 |
$112 |
$58 |
$299 |
$0.4 |
-$83 |
1.4 |
Feb-99 |
1.1 |
$10.00 |
$280 |
| ARGONAUT TECHNOLOGIES |
$0.96 |
40% |
-45% |
$20 |
$9 |
$0 |
$10 |
$0.1 |
-$8 |
1.2 |
Jul-00 |
0.1 |
$15.00 |
$253 |
| ARQULE |
$5.79 |
73% |
19% |
$167 |
$60 |
$6 |
$112 |
$0.4 |
-$1 |
116.3 |
Oct-96 |
0.5 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$9.52 |
80% |
67% |
$276 |
$105 |
$0 |
$171 |
$0.7 |
-$14 |
7.3 |
Nov-01 |
1.3 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$5.78 |
51% |
-16% |
$126 |
$24 |
$0 |
$101 |
$2.2 |
-$20 |
1.2 |
Mar-94 |
0.9 |
$6.50 |
$47 |
| DISCOVERY PARTNERS INTER. |
$4.71 |
72% |
-23% |
$123 |
$74 |
$0 |
$49 |
$0.2 |
na |
na |
Jul-00 |
0.3 |
$18.00 |
$428 |
| KOSAN BIOSCIENCES |
$6.93 |
46% |
-30% |
$201 |
$70 |
$4 |
$135 |
$1.0 |
-$21 |
3.4 |
Oct-00 |
0.5 |
$14.00 |
$341 |
| SYMYX TECHNOLOGIES |
$30.05 |
93% |
46% |
$966 |
$146 |
$0 |
$821 |
$3.5 |
na |
na |
Nov-99 |
2.1 |
$14.00 |
$398 |
| VERTEX PHARMACEUTICALS |
$10.57 |
87% |
2% |
$849 |
$481 |
$315 |
$683 |
$0.9 |
-$177 |
2.7 |
Jul-91 |
2.3 |
$4.50 |
$85 |
| Chemistry Average |
|
64% |
-3% |
$329 |
$122 |
|
$245 |
$1.0 |
-$44 |
17.4 |
|
1.0 |
|
|
| Chemistry Median |
|
68% |
-20% |
$204 |
$89 |
|
$124 |
$0.6 |
-$21 |
3.0 |
|
0.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACADIA PHARMACEUTICALS |
$6.77 |
85% |
na |
$114 |
$51 |
$1 |
$64 |
$0.6 |
-$24 |
2.2 |
May-04 |
1.0 |
$7.00 |
$118 |
| ADOLOR CORP. |
$9.92 |
55% |
-50% |
$388 |
$184 |
$0 |
$204 |
$1.6 |
-$52 |
3.5 |
Nov-00 |
0.7 |
$15.00 |
$407 |
| CEPHALON |
$50.88 |
83% |
5% |
$2,935 |
$1,218 |
$1,412 |
$3,129 |
$1.9 |
-$27 |
44.8 |
Apr-91 |
2.8 |
$18.00 |
$155 |
| CORCEPT THERAPEUTICS |
$6.25 |
49% |
na |
$142 |
$8 |
$0 |
$134 |
$19.1 |
-$14 |
0.6 |
Apr-04 |
0.5 |
$12.00 |
$272 |
| DOV PHARMACEUTICAL |
$18.05 |
89% |
35% |
$387 |
$43 |
$15 |
$359 |
$10.0 |
-$34 |
1.3 |
Apr-02 |
1.4 |
$13.00 |
$188 |
| GUILFORD PHARMACEUTICALS |
$4.95 |
51% |
-27% |
$220 |
$86 |
$92 |
$226 |
$0.9 |
-$85 |
1.0 |
Jun-94 |
0.9 |
$5.33 |
$30 |
| INDEVUS PHARMACEUTICALS |
$5.96 |
58% |
1% |
$280 |
$44 |
$72 |
$308 |
$11.4 |
-$74 |
0.6 |
Mar-90 |
3.0 |
$2.00 |
$31 |
| MEMORY PHARMACEUTICALS |
$5.32 |
49% |
na |
$109 |
$18 |
$0 |
$91 |
$1.2 |
-$24 |
0.8 |
Apr-04 |
0.8 |
$7.00 |
$143 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$4.42 |
63% |
-24% |
$118 |
$20 |
$0 |
$98 |
$8.9 |
-$4 |
4.9 |
Feb-94 |
0.6 |
$8.00 |
$30 |
| NEUROCRINE BIOSCIENCES |
$49.30 |
71% |
-10% |
$1,798 |
$366 |
$47 |
$1,479 |
$4.7 |
-$45 |
8.2 |
May-96 |
4.7 |
$10.50 |
$172 |
| NEW RIVER PHARMACEUTICALS |
$14.96 |
67% |
na |
$266 |
$34 |
$0 |
$232 |
$10.5 |
-$5 |
7.5 |
Aug-04 |
1.9 |
$8.00 |
$142 |
| NYMOX PHARMACEUTICAL CORP. |
$2.81 |
52% |
-17% |
$70 |
$0 |
$1 |
$70 |
$3.3 |
-$4 |
na |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$7.21 |
73% |
4% |
$314 |
$120 |
$0 |
$195 |
$6.5 |
-$36 |
3.3 |
Jul-00 |
0.6 |
$12.00 |
$319 |
| PHARMOS CORP. |
$1.42 |
29% |
-59% |
$134 |
$59 |
$16 |
$92 |
$1.7 |
-$21 |
2.8 |
Jul-83 |
0.1 |
$20.00 |
$16 |
| RENOVIS |
$14.38 |
82% |
na |
$353 |
$103 |
$3 |
$253 |
$3.5 |
-$39 |
2.6 |
Feb-04 |
1.2 |
$12.00 |
$295 |
| STEMCELLS |
$4.23 |
68% |
114% |
$230 |
$7 |
$2 |
$224 |
$8.0 |
-$13 |
0.5 |
Mar-92 |
0.4 |
$11.00 |
$82 |
| TITAN PHARMACEUTICALS |
$3.22 |
55% |
10% |
$104 |
$52 |
$0 |
$52 |
$0.9 |
-$22 |
2.3 |
Jan-96 |
0.6 |
$5.00 |
$66 |
| CNS Average |
|
63% |
-2% |
$468 |
$142 |
|
$424 |
$5.6 |
-$31 |
5.4 |
|
1.3 |
|
|
| CNS Median |
|
63% |
-4% |
$230 |
$51 |
|
$204 |
$3.5 |
-$24 |
2.5 |
|
0.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ABGENIX |
$10.34 |
53% |
-16% |
$921 |
$257 |
$249 |
$913 |
$2.3 |
-$242 |
1.1 |
Jul-98 |
5.2 |
$2.00 |
$86 |
| ACUSPHERE |
$6.13 |
58% |
-30% |
$109 |
$40 |
$0 |
$69 |
$1.2 |
-$30 |
1.3 |
Oct-03 |
0.4 |
$14.00 |
$200 |
| AEROGEN |
$1.96 |
49% |
-11% |
$10 |
$12 |
$0 |
($2) |
($0.0) |
-$35 |
0.3 |
Nov-00 |
0.2 |
$12.00 |
$233 |
| ALKERMES |
$14.09 |
82% |
4% |
$1,270 |
$110 |
$127 |
$1,287 |
$3.0 |
-$145 |
0.8 |
Jul-91 |
2.8 |
$5.00 |
$70 |
| ANDRX CORP. |
$21.83 |
71% |
-9% |
$1,591 |
$332 |
$12 |
$1,271 |
$0.6 |
na |
na |
Jun-96 |
7.3 |
$3.00 |
$155 |
| ARADIGM CORP. |
$1.73 |
59% |
1% |
$111 |
$11 |
$0 |
$100 |
$0.5 |
-$30 |
0.4 |
Jun-96 |
0.2 |
$11.00 |
$114 |
| BIODELIVERY SCIENCES INTL. |
$3.52 |
77% |
30% |
$25 |
$2 |
$1 |
$24 |
$1.3 |
-$5 |
0.4 |
na |
na |
na |
na |
| DEPOMED |
$5.40 |
60% |
-24% |
$187 |
$31 |
$10 |
$166 |
$2.2 |
-$30 |
1.0 |
Nov-97 |
0.9 |
$6.10 |
$33 |
| DOR BIOPHARMA |
$0.64 |
41% |
-18% |
$27 |
$5 |
$0 |
$23 |
$5.7 |
-$6 |
0.8 |
na |
na |
na |
na |
| DURECT CORP. |
$3.28 |
77% |
31% |
$170 |
$52 |
$62 |
$180 |
$1.7 |
-$30 |
1.8 |
Sep-00 |
0.3 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$4.02 |
46% |
-26% |
$74 |
$23 |
$40 |
$92 |
$0.8 |
-$35 |
0.7 |
Feb-89 |
0.8 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$13.72 |
75% |
15% |
$601 |
$107 |
$400 |
$894 |
$2.8 |
-$29 |
3.6 |
Feb-84 |
9.1 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$19.49 |
61% |
-27% |
$418 |
$110 |
$2 |
$310 |
$2.1 |
-$4 |
31.6 |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY CORP. |
$0.75 |
40% |
-44% |
$26 |
$3 |
$2 |
$25 |
$1.0 |
-$20 |
0.2 |
na |
na |
na |
na |
| GENETRONICS BIOMEDICAL CORP. |
$3.94 |
51% |
-21% |
$72 |
$11 |
$0 |
$61 |
$3.1 |
-$9 |
1.2 |
na |
na |
na |
na |
| KOS PHARMACEUTICALS |
$37.64 |
63% |
-12% |
$1,499 |
$108 |
$30 |
$1,422 |
$1.6 |
na |
na |
Mar-97 |
2.5 |
$15.00 |
$233 |
| MACROCHEM CORP. |
$0.73 |
39% |
-14% |
$28 |
$10 |
$0 |
$18 |
$1.1 |
-$9 |
1.2 |
Feb-85 |
0.2 |
$3.00 |
$13 |
| MEDICIS PHARMACEUTICAL CORP. |
$35.11 |
78% |
-51% |
$1,921 |
$628 |
$471 |
$1,763 |
$5.7 |
na |
na |
na |
na |
na |
na |
| NASTECH PHARMACEUTICAL CO. |
$12.10 |
73% |
26% |
$163 |
$69 |
$11 |
$105 |
$1.3 |
-$30 |
2.3 |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$20.24 |
81% |
49% |
$1,699 |
$464 |
$215 |
$1,450 |
$2.2 |
-$88 |
5.3 |
May-94 |
5.4 |
$3.75 |
$65 |
| NOVAVAX |
$3.26 |
47% |
-46% |
$129 |
$16 |
$42 |
$155 |
$1.3 |
-$31 |
0.5 |
na |
na |
na |
na |
| NOVEN PHARMACEUTICALS |
$17.06 |
66% |
12% |
$400 |
$113 |
$0 |
$288 |
$0.9 |
na |
na |
May-88 |
31.0 |
$0.55 |
$5 |
| SEPRACOR |
$59.37 |
96% |
148% |
$6,239 |
$421 |
$1,192 |
$7,010 |
$7.1 |
-$324 |
1.3 |
Sep-91 |
11.9 |
$5.00 |
$168 |
| Delivery Average |
|
63% |
-1% |
$769 |
$128 |
|
$766 |
$2.1 |
-$60 |
2.9 |
|
5.2 |
|
|
| Delivery Median |
|
61% |
-12% |
$170 |
$52 |
|
$166 |
$1.6 |
-$30 |
1.1 |
|
2.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCED MAGNETICS |
$15.72 |
90% |
21% |
$126 |
$17 |
$0 |
$109 |
$4.9 |
-$3 |
5.5 |
na |
na |
na |
na |
| BIOSITE |
$61.54 |
97% |
113% |
$997 |
$75 |
$20 |
$942 |
$1.2 |
na |
na |
Feb-97 |
5.1 |
$12.00 |
$149 |
| CHOLESTECH CORP. |
$8.20 |
80% |
7% |
$118 |
$17 |
$0 |
$100 |
$0.5 |
-$1 |
12.5 |
Jun-92 |
1.6 |
$5.00 |
$32 |
| DIAGNOSTIC PRODUCTS CORP. |
$55.05 |
97% |
20% |
$1,606 |
$77 |
$17 |
$1,546 |
$0.7 |
na |
na |
Jun-82 |
13.8 |
$4.00 |
$43 |
| DIGENE CORP. |
$26.15 |
54% |
-35% |
$522 |
$49 |
$3 |
$475 |
$1.6 |
na |
na |
May-96 |
2.3 |
$11.50 |
$128 |
| ENZO BIOCHEM |
$19.47 |
94% |
9% |
$631 |
$79 |
$0 |
$552 |
$2.5 |
-$2 |
39.7 |
Jun-80 |
22.4 |
$0.87 |
$8 |
| EPIX PHARMACEUTICALS |
$17.91 |
68% |
10% |
$414 |
$71 |
$0 |
$343 |
$4.0 |
-$20 |
3.5 |
Feb-97 |
2.6 |
$7.00 |
$59 |
| EXACT SCIENCES CORP. |
$3.83 |
38% |
-62% |
$100 |
$63 |
$0 |
$37 |
$0.5 |
-$17 |
3.8 |
Jan-01 |
0.3 |
$14.00 |
$261 |
| GEN-PROBE ORPORATED |
$45.21 |
84% |
24% |
$2,253 |
$198 |
$0 |
$2,055 |
$2.8 |
na |
na |
Sep-87 |
6.5 |
$7.00 |
$103 |
| IDEXX LABORATORIES |
$54.59 |
79% |
18% |
$1,837 |
$230 |
$1 |
$1,609 |
$0.7 |
na |
na |
Jun-91 |
14.6 |
$3.75 |
$76 |
| IMMUCOR |
$23.51 |
81% |
159% |
$1,053 |
$13 |
$14 |
$1,054 |
$2.9 |
na |
na |
na |
na |
na |
na |
| IMMUNICON |
$6.98 |
66% |
na |
$161 |
$17 |
$7 |
$151 |
$1.5 |
-$29 |
0.6 |
Apr-04 |
0.9 |
$8.00 |
$185 |
| LUMINEX CORP. |
$8.88 |
66% |
-5% |
$277 |
$37 |
$0 |
$240 |
$1.8 |
-$4 |
8.4 |
Mar-00 |
0.5 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$51.20 |
70% |
-21% |
$1,511 |
$60 |
$82 |
$1,532 |
$4.0 |
na |
na |
Nov-93 |
7.3 |
$7.00 |
$54 |
| MATRITECH |
$1.06 |
53% |
-44% |
$45 |
$8 |
$2 |
$39 |
$0.6 |
-$13 |
0.7 |
Jul-92 |
0.2 |
$5.00 |
$22 |
| MERIDIAN BIOSCIENCE |
$17.55 |
85% |
68% |
$264 |
$3 |
$22 |
$284 |
$1.2 |
na |
na |
na |
na |
na |
na |
| ORASURE TECHNOLOGIES |
$6.72 |
56% |
-16% |
$299 |
$65 |
$3 |
$238 |
$1.4 |
na |
na |
na |
na |
na |
na |
| QUIDEL CORP. |
$5.08 |
36% |
-53% |
$161 |
$38 |
$10 |
$133 |
$0.5 |
-$9 |
4.1 |
Aug-81 |
0.5 |
$10.00 |
$19 |
| SONUS PHARMACEUTICALS |
$3.53 |
40% |
-31% |
$75 |
$13 |
$0 |
$62 |
$1.5 |
-$15 |
0.9 |
Oct-95 |
0.5 |
$7.00 |
$60 |
| STRATAGENE |
$7.75 |
65% |
99% |
$171 |
$8 |
$0 |
$163 |
$1.1 |
na |
na |
na |
na |
na |
na |
| TRINITY BIOTECH PLC |
$2.96 |
62% |
-47% |
$166 |
$23 |
$22 |
$166 |
$0.3 |
na |
na |
na |
na |
na |
na |
| XENOGEN |
$7.00 |
86% |
na |
$103 |
$39 |
$0 |
$64 |
$0.5 |
-$21 |
1.9 |
Jul-04 |
1.0 |
$7.00 |
$103 |
| Diagnostic/imag. Average |
|
70% |
12% |
$586 |
$55 |
|
$541 |
$1.7 |
-$12 |
7.4 |
|
5.0 |
|
|
| Diagnostic/imag. Median |
|
69% |
8% |
$270 |
$39 |
|
$239 |
$1.3 |
-$13 |
3.8 |
|
2.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AASTROM BIOSCIENCES |
$1.42 |
47% |
7% |
$131 |
$8 |
$0 |
$123 |
$2.8 |
-$11 |
0.8 |
Feb-97 |
0.2 |
$7.00 |
$88 |
| AVIGEN |
$3.26 |
41% |
-45% |
$66 |
$70 |
$9 |
$5 |
$0.1 |
-$18 |
3.9 |
May-96 |
0.4 |
$8.00 |
$58 |
| CELL GENESYS |
$8.10 |
50% |
-37% |
$364 |
$204 |
$148 |
$308 |
$1.1 |
-$104 |
2.0 |
Jan-93 |
0.7 |
$11.00 |
$120 |
| CORAUTUS GENETICS |
$5.38 |
70% |
20% |
$73 |
$13 |
$4 |
$64 |
$2.1 |
-$9 |
1.4 |
na |
na |
na |
na |
| GENVEC |
$1.63 |
37% |
-51% |
$91 |
$20 |
$6 |
$76 |
$0.9 |
-$19 |
1.1 |
Dec-00 |
0.2 |
$9.50 |
$186 |
| INTROGEN THERAPEUTICS |
$8.44 |
83% |
0% |
$229 |
$26 |
$7 |
$211 |
$2.9 |
-$22 |
1.2 |
Oct-00 |
1.1 |
$8.00 |
$167 |
| SIRNA THERAPEUTICS |
$3.17 |
49% |
-39% |
$120 |
$24 |
$3 |
$99 |
$1.4 |
-$25 |
0.9 |
Apr-96 |
0.3 |
$10.00 |
$59 |
| TARGETED GENETICS CORP. |
$1.55 |
47% |
-29% |
$127 |
$37 |
$12 |
$102 |
$1.1 |
-$18 |
2.1 |
May-94 |
0.3 |
$6.00 |
$54 |
| TRANSGENE SA |
$2.80 |
64% |
9% |
$84 |
$45 |
$3 |
$42 |
$0.3 |
na |
na |
Mar-98 |
0.1 |
$43.50 |
$212 |
| TRANSKARYOTIC THERAPIES |
$25.39 |
96% |
63% |
$883 |
$151 |
$0 |
$732 |
$2.3 |
-$81 |
1.9 |
Oct-96 |
1.7 |
$15.00 |
$234 |
| VALENTIS |
$2.50 |
24% |
-7% |
$33 |
$2 |
$0 |
$31 |
$1.6 |
-$15 |
0.1 |
Sep-97 |
0.2 |
$12.00 |
$161 |
| VICAL |
$4.70 |
58% |
-4% |
$110 |
$89 |
$12 |
$33 |
$0.2 |
-$21 |
4.2 |
Mar-93 |
0.9 |
$5.00 |
$52 |
| Gene therapy Average |
|
55% |
-10% |
$193 |
$57 |
|
$152 |
$1.4 |
-$31 |
1.8 |
|
0.6 |
|
|
| Gene therapy Median |
|
49% |
-6% |
$115 |
$31 |
|
$88 |
$1.3 |
-$19 |
1.4 |
|
0.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCIS |
$3.82 |
38% |
-49% |
$87 |
$49 |
$3 |
$41 |
$0.5 |
-$34 |
1.5 |
Oct-03 |
0.4 |
$10.00 |
$224 |
| ANADYS PHARMACEUTICALS |
$7.49 |
86% |
na |
$167 |
$41 |
$2 |
$128 |
$1.6 |
-$44 |
0.9 |
Mar-04 |
1.1 |
$7.00 |
$156 |
| AVANT IMMUNOTHERAPEUTICS |
$2.01 |
51% |
-27% |
$149 |
$37 |
$0 |
$112 |
$1.9 |
-$16 |
2.4 |
May-86 |
0.5 |
$4.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$11.83 |
74% |
-3% |
$477 |
$189 |
$197 |
$485 |
$1.7 |
-$72 |
2.6 |
Oct-96 |
2.0 |
$6.00 |
$55 |
| DYNAVAX TECHNOLOGIES |
$8.00 |
80% |
na |
$197 |
$77 |
$0 |
$120 |
$2.7 |
-$12 |
6.6 |
Feb-04 |
1.1 |
$7.50 |
$185 |
| EPIMMUNE |
$1.66 |
56% |
-8% |
$27 |
$5 |
$0 |
$22 |
$0.6 |
-$3 |
1.4 |
Nov-91 |
0.0 |
$91.00 |
$167 |
| GENELABS TECHNOLOGIES |
$1.20 |
37% |
-58% |
$106 |
$25 |
$0 |
$81 |
$1.1 |
-$12 |
2.1 |
Jun-91 |
0.1 |
$9.13 |
$160 |
| IDENIX PHARMACEUTICALS |
$17.15 |
91% |
na |
$822 |
$113 |
$0 |
$710 |
$5.0 |
na |
na |
Jul-04 |
1.2 |
$14.00 |
$684 |
| IMMUNE RESPONSE CORP. |
$1.61 |
66% |
7% |
$78 |
$4 |
$4 |
$79 |
$1.7 |
-$20 |
0.2 |
May-90 |
0.1 |
$28.00 |
$77 |
| INHIBITEX |
$8.04 |
63% |
na |
$147 |
$43 |
$2 |
$106 |
$1.7 |
-$58 |
0.7 |
Jun-04 |
1.1 |
$7.00 |
$128 |
| INTERMUNE |
$13.26 |
62% |
-43% |
$425 |
$302 |
$267 |
$390 |
$1.5 |
-$52 |
5.8 |
Mar-00 |
0.7 |
$20.00 |
$433 |
| INTRABIOTICS PHARMACEUTICALS |
$4.08 |
21% |
-75% |
$36 |
$54 |
$0 |
($18) |
($1.8) |
-$21 |
2.6 |
Apr-00 |
0.3 |
$15.00 |
$419 |
| NABI BIOPHARMACEUTICALS |
$14.65 |
82% |
15% |
$856 |
$108 |
$24 |
$771 |
$1.1 |
-$70 |
1.5 |
na |
na |
na |
na |
| SIGA TECHNOLOGIES |
$1.66 |
59% |
-28% |
$41 |
$1 |
$0 |
$39 |
$2.3 |
-$8 |
0.2 |
Sep-97 |
0.3 |
$5.00 |
$32 |
| TRIMERIS |
$14.17 |
75% |
-32% |
$310 |
$64 |
$0 |
$246 |
$2.5 |
-$65 |
1.0 |
Oct-97 |
1.2 |
$12.00 |
$120 |
| VAXGEN |
$17.00 |
91% |
115% |
$499 |
na |
na |
na |
na |
-$37 |
na |
Jul-99 |
1.3 |
$13.00 |
$146 |
| VICURON PHARMACEUTICALS |
$17.41 |
71% |
-7% |
$1,048 |
$199 |
$9 |
$857 |
$23.2 |
-$96 |
2.1 |
Sep-00 |
1.6 |
$11.00 |
$249 |
| VION PHARMACEUTICALS |
$4.69 |
85% |
197% |
$262 |
$48 |
$0 |
$214 |
$7.4 |
-$15 |
3.2 |
Aug-95 |
1.2 |
$4.00 |
$32 |
| VIROLOGIC |
$2.79 |
63% |
-26% |
$151 |
$9 |
$0 |
$142 |
$0.8 |
-$6 |
1.5 |
May-00 |
0.4 |
$7.00 |
$137 |
| VIROPHARMA ORPORATED |
$3.25 |
87% |
17% |
$87 |
$105 |
$128 |
$109 |
$1.2 |
-$22 |
4.9 |
Nov-96 |
0.5 |
$7.00 |
$65 |
| XOMA LTD |
$2.59 |
34% |
-61% |
$222 |
$59 |
$56 |
$219 |
$1.0 |
-$84 |
0.7 |
Jun-86 |
0.2 |
$16.00 |
$140 |
| Infection Average |
|
65% |
-4% |
$295 |
$77 |
|
$243 |
$2.9 |
-$37 |
2.2 |
|
0.8 |
|
|
| Infection Median |
|
66% |
-26% |
$167 |
$52 |
|
$124 |
$1.6 |
-$28 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMYLIN PHARMACEUTICALS |
$23.36 |
87% |
5% |
$2,204 |
$188 |
$177 |
$2,194 |
$9.8 |
-$158 |
1.2 |
Jan-92 |
1.7 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$6.39 |
72% |
-18% |
$412 |
$153 |
$125 |
$385 |
$1.4 |
-$222 |
0.7 |
Aug-99 |
0.5 |
$13.00 |
$449 |
| INSMED |
$2.20 |
51% |
-26% |
$85 |
$16 |
$0 |
$68 |
$3.4 |
-$36 |
0.5 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$11.57 |
58% |
149% |
$360 |
$51 |
$0 |
$309 |
$12.9 |
na |
na |
Jul-00 |
1.2 |
$10.00 |
$194 |
| MANNKIND |
$15.75 |
65% |
na |
$517 |
$106 |
$0 |
$411 |
$1.8 |
-$73 |
1.5 |
Jul-04 |
1.1 |
$14.00 |
$446 |
| METABASIS THERAPEUTICS |
$7.25 |
98% |
na |
$132 |
$53 |
$0 |
$78 |
$1.0 |
-$15 |
3.7 |
Jun-04 |
1.0 |
$7.00 |
$127 |
| NPS PHARMACEUTICALS |
$18.28 |
50% |
-40% |
$709 |
$225 |
$192 |
$676 |
$2.5 |
-$166 |
1.4 |
May-94 |
3.3 |
$5.50 |
$40 |
| SAVIENT PHARMACEUTICALS |
$2.71 |
49% |
-41% |
$164 |
$1 |
$11 |
$174 |
$0.4 |
-$128 |
0.0 |
Sep-83 |
0.2 |
$13.00 |
$68 |
| TERCICA |
$10.00 |
83% |
na |
$246 |
$63 |
$0 |
$183 |
$4.5 |
-$46 |
1.4 |
Mar-04 |
1.1 |
$9.00 |
$221 |
| VIVUS |
$4.45 |
60% |
17% |
$170 |
$35 |
$0 |
$135 |
$1.1 |
-$20 |
1.8 |
Apr-94 |
0.6 |
$7.00 |
$164 |
| ZONAGEN |
$4.33 |
73% |
134% |
$22 |
$8 |
$0 |
$14 |
$3.5 |
-$3 |
2.8 |
Mar-93 |
0.8 |
$5.50 |
$19 |
| Metabolic Average |
|
68% |
23% |
$456 |
$82 |
|
$421 |
$3.8 |
-$86 |
1.5 |
|
1.2 |
|
|
| Metabolic Median |
|
65% |
-6% |
$246 |
$53 |
|
$183 |
$2.5 |
-$59 |
1.4 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALNYLAM PHARMACEUTICALS |
$7.47 |
68% |
na |
$150 |
$48 |
$2 |
$104 |
$1.7 |
-$31 |
1.6 |
May-04 |
1.2 |
$6.00 |
$121 |
| AUXILIUM PHARMACEUTICALS |
$8.85 |
87% |
na |
$182 |
$54 |
$0 |
$129 |
$0.9 |
-$32 |
1.7 |
Jul-04 |
1.2 |
$7.50 |
$160 |
| BARRIER THERAPEUTICS |
$16.60 |
82% |
na |
$363 |
$37 |
$0 |
$326 |
$8.0 |
-$40 |
0.9 |
Apr-04 |
1.1 |
$15.00 |
$328 |
| CRITICAL THERAPEUTICS |
$8.00 |
45% |
na |
$192 |
$54 |
$1 |
$140 |
$1.4 |
-$32 |
1.7 |
May-04 |
1.1 |
$7.00 |
$168 |
| EYETECH PHARMACEUTICALS |
$45.50 |
93% |
na |
$1,891 |
$239 |
$2 |
$1,653 |
$10.4 |
-$124 |
1.9 |
Jan-04 |
2.2 |
$21.00 |
$873 |
| MOMENTA PHARMACEUTICALS |
$7.06 |
74% |
na |
$256 |
$67 |
$0 |
$189 |
$5.2 |
-$16 |
4.3 |
Jun-04 |
1.1 |
$6.50 |
$236 |
| SANTARUS |
$9.04 |
57% |
na |
$328 |
$76 |
$1 |
$252 |
$3.6 |
-$68 |
1.1 |
Mar-04 |
1.0 |
$9.00 |
$326 |
| Other Average |
|
72% |
na |
$480 |
$82 |
|
$399 |
$4.5 |
-$49 |
1.9 |
|
1.3 |
|
|
| Other Median |
|
74% |
na |
$256 |
$54 |
|
$189 |
$3.6 |
-$32 |
1.7 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMGEN |
$64.15 |
96% |
4% |
$81,479 |
$5,003 |
$3,087 |
$79,563 |
$6.2 |
na |
na |
Jun-83 |
183.3 |
$0.35 |
$175 |
| BIOGEN IDEC |
$66.61 |
98% |
81% |
$22,218 |
$948 |
$861 |
$22,131 |
$5.9 |
na |
na |
Sep-91 |
26.6 |
$2.50 |
$131 |
| CHIRON CORP. |
$33.33 |
62% |
-42% |
$6,227 |
$698 |
$1,088 |
$6,617 |
$1.2 |
na |
na |
Aug-83 |
11.1 |
$3.00 |
$98 |
| GENENTECH |
$54.44 |
80% |
16% |
$57,141 |
$1,815 |
$1,340 |
$56,666 |
$9.1 |
na |
na |
Oct-80 |
37.5 |
$1.45 |
$246 |
| GENZYME CORP. |
$58.07 |
96% |
18% |
$13,325 |
$1,004 |
$1,423 |
$13,745 |
$2.4 |
na |
na |
Jun-86 |
23.2 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$34.99 |
89% |
20% |
$15,148 |
$1,036 |
$345 |
$14,457 |
$10.1 |
na |
na |
Jan-92 |
9.3 |
$3.75 |
$210 |
| MEDIMMUNE |
$27.11 |
94% |
7% |
$6,743 |
$561 |
$507 |
$6,688 |
$4.1 |
-$292 |
1.9 |
May-91 |
17.6 |
$1.54 |
$114 |
| Revenue-driven Average |
|
88% |
16% |
$28,897 |
$1,581 |
|
$28,552 |
$5.6 |
na |
na |
|
44.1 |
|
|
| Revenue-driven Median |
|
94% |
16% |
$15,148 |
$1,004 |
|
$14,457 |
$5.9 |
na |
na |
|
23.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| DIVERSA CORP. |
$8.74 |
71% |
-6% |
$382 |
$111 |
$20 |
$290 |
$0.8 |
-$32 |
3.5 |
Feb-00 |
0.4 |
$24.00 |
$840 |
| DYAX CORP. |
$7.22 |
46% |
-11% |
$228 |
$60 |
$10 |
$178 |
$1.6 |
-$33 |
1.8 |
Aug-00 |
0.5 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$5.90 |
60% |
-9% |
$338 |
$162 |
$230 |
$406 |
$0.9 |
-$105 |
1.5 |
May-91 |
0.6 |
$10.00 |
$104 |
| LIGAND PHARMACEUTICALS |
$11.64 |
47% |
-21% |
$861 |
$76 |
$174 |
$958 |
$2.1 |
-$57 |
1.3 |
Nov-92 |
1.4 |
$8.27 |
$131 |
| NEUROGEN CORP. |
$9.36 |
82% |
11% |
$321 |
$65 |
$14 |
$270 |
$1.7 |
-$17 |
3.8 |
Oct-89 |
1.6 |
$6.00 |
$35 |
| ONYX PHARMACEUTICALS |
$32.39 |
54% |
15% |
$1,142 |
$237 |
$0 |
$905 |
$56.6 |
-$52 |
4.5 |
May-96 |
2.7 |
$12.00 |
$105 |
| REGENERON PHARMACEUTICALS |
$9.21 |
54% |
-37% |
$513 |
$309 |
$200 |
$405 |
$6.3 |
-$58 |
5.3 |
Apr-91 |
0.4 |
$22.00 |
$330 |
| SENOMYX |
$8.28 |
70% |
na |
$209 |
$48 |
$0 |
$161 |
$2.2 |
-$14 |
3.5 |
Jun-04 |
1.4 |
$6.00 |
$151 |
| Screening Average |
|
61% |
-8% |
$499 |
$133 |
|
$447 |
$9.0 |
-$46 |
3.2 |
|
1.1 |
|
|
| Screening Median |
|
57% |
-9% |
$360 |
$94 |
|
$347 |
$1.9 |
-$43 |
3.5 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
12/31/04 Close
|
% of 52wk High |
% change since 12/31/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Surviva Index (Yrs)l |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CARRINGTON LABORATORIES |
$6.13 |
89% |
49% |
$65 |
$2 |
$4 |
$67 |
$0.3 |
-$0 |
17.1 |
na |
na |
na |
na |
| CELLEGY PHARMACEUTICALS |
$2.87 |
41% |
-8% |
$75 |
$6 |
$0 |
$69 |
$3.4 |
-$11 |
0.6 |
Aug-95 |
0.5 |
$6.25 |
$24 |
| CURATIVE HEALTH SERVICES |
$6.85 |
47% |
-50% |
$89 |
$3 |
$0 |
$86 |
$0.2 |
-$13 |
0.2 |
Jun-91 |
0.9 |
$7.50 |
$74 |
| LIFECELL CORP. |
$10.22 |
89% |
65% |
$291 |
$19 |
$0 |
$272 |
$1.6 |
na |
na |
Feb-92 |
1.3 |
$7.75 |
$27 |
| LIFECORE BIOMEDICAL |
$11.26 |
74% |
87% |
$146 |
$8 |
$0 |
$138 |
$0.7 |
na |
na |
na |
na |
na |
na |
| Wound Average |
|
68% |
29% |
$133 |
$8 |
|
$126 |
$1.2 |
-$8 |
6.0 |
|
0.9 |
|
|
| Wound Median |
|
74% |
49% |
$89 |
$6 |
|
$86 |
$0.7 |
-$11 |
0.6 |
|
0.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Overall Average |
|
66% |
3% |
$1,345 |
$155 |
|
$1,280 |
$3.0 |
-$49 |
3.6 |
|
3.3 |
|
|
| Overall Median |
|
66% |
-3% |
$274 |
$62 |
|
$225 |
$1.7 |
-$31 |
1.8 |
|
1.0 |
|
originally published 01/24/2005 |